Name (Synonyms) | Correlation | |
---|---|---|
drug1017 | Guanfacine hydrochloride (SPD503) Wiki | 1.00 |
drug236 | Atomoxetine hydrochloride Wiki | 1.00 |
drug1822 | Placebo Wiki | 0.06 |
Name (Synonyms) | Correlation | |
---|---|---|
D006948 | Hyperkinesis NIH | 0.71 |
D001289 | Attention Deficit Disorder with Hyperactivity NIH | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002487 | Hyperkinetic movements HPO | 0.71 |
HP:0007018 | Attention deficit hyperactivity disorder HPO | 0.50 |
There is one clinical trial.
Sars-Cov2 (COVID-19) may invade the CNS inducing neurological diseases such as anosmia, ageusia, encephalitis, ischemic or hemorrhagic stroke. Management of severe neurological complications in COVID-19 patients may require ventricular cerebrospinal fluid drainage and cranial decompression. During surgery, cerebrospinal fluid, meninges and brain parenchyma can be safely removed from the patient. In this study, COVID-19 patients will be evaluated first, for the presence of Sars-Cov2 in the cerebrospinal fluid and/or biopsies and second, for the consequences of Sars-Cov2 neuroinfection in terms of inflammatory and immune responses.
Description: COVID-19 RT-PCR test
Measure: Percentage of patients with COVID-19 positive samples/biopsies Time: At the time of the inclusion